Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Investors Business Daily

Musk Reportedly Suspends Twitter Work On Crypto Wallet, Boeing's Jeppesen Hit By Potential Ransomware Attack, Lyft Cuts Workforce: Top Stories Friday, Nov. 04

Reuters

Benzinga

Dow Jones Futures Rise: Jobs Report Key For Market Rally As Apple, Google Plunge

Friday's jobs report will reinforce or ease Fed chief Powell's hawkish comments. Apple, Google were market rally drags.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts

Amgen stock popped Friday after the drugmaker sweetened its 2022 outlook following a third-quarter beat and strong Evenity sales.

Investors Business Daily

Looking At Amgen's Recent Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Benzinga

1 Biotech Stock to Double Down on in Q4

Leading drug maker Amgen (AMGN) delivered impressive second-quarter results. The company is well-positioned for solid long-term growth, driven by its diversified and growing product portfolio, rising demand from a rapidly aging population, and continued advancements in science and technology. Given its high profitability, attractive dividends, and bright growth prospects, we…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

Investors Business Daily

Buy, Hold, Sell: How This Moving Average Improves Your Trading Every Time

Putting some simple math to calculate the 200-day moving average of a stock can help investors make better decisions.

Investors Business Daily

Amgen Stock Shows Market Leadership With Jump To 90 RS Rating

Amgen sees its Relative Strength Rating reach the elite 90-plus level.

Investors Business Daily

Amgen is Our Growth Stock of the Week…

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

StockNews.com

Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity Treatments

Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

Upgrades

Benzinga

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Amgen Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades.

Investors Business Daily

Why Amgen's Cancer Drug Results Gave This Small Cap A Big Boost

Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival Mirati along for the ride.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

StockNews.com

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Falls As Powell Warns Of 'Some Pain' To Fight Inflation

The Dow Jones Industrial Average reversed lower Friday, as Federal Reserve Chairman Jerome Powell warned of "some pain" to fight inflation.

Investors Business Daily

Take Advantage Of Low Volatility In Amgen Stock With Options

Amgen is showing very low implied volatility compared to recent history. That could mean it’s a good time to buy an option strangle.

Investors Business Daily

Dow Jones Falls After Key Economic Data; Peloton Dives 18% On Earnings

The Dow Jones Industrial Average fell Thursday after key economic data. Peloton dived 18% on earnings, while Tesla stock rallied post-split.

Investors Business Daily

Dow Jones Falls As Tesla Climbs Ahead Of 3:1 Stock Split

The Dow Jones Industrial Average fell Wednesday, extending a losing streak. Tesla stock climbed ahead of Thursday's 3:1 stock split.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Investors Business Daily

Dow Jones Falls After Stock Market Plunge; Zoom Video Dives On Earnings

The Dow Jones Industrial Average fell Tuesday, adding to Monday's stock market plunge. Zoom Video stock dived on earnings.

StockNews.com

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

1 … 9 10 11 12

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Brian Abrahams

67 stories

Jaimini DesaiJaimini Desai

59 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.